Daily Stock Analysis, GLMD, Galmed Pharmaceuticals Ltd, priceseries

Galmed Pharmaceuticals Ltd. Daily Stock Analysis
Stock Information
Open
7.94
Close
8.00
High
8.27
Low
7.61
Previous Close
7.99
Daily Price Gain
0.01
YTD High
9.37
YTD High Date
Apr 3, 2019
YTD Low
6.62
YTD Low Date
Jan 2, 2019
YTD Price Change
0.40
YTD Gain
5.26%
52 Week High
27.06
52 Week High Date
Jun 12, 2018
52 Week Low
5.36
52 Week Low Date
May 9, 2018
52 Week Price Change
1.82
52 Week Gain
29.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
4.30
Mar 7. 2017
4.76
7 Trading Days
10.73%
Link
LONG
Apr 27. 2017
5.14
May 1. 2017
5.46
2 Trading Days
6.23%
Link
LONG
Jun 13. 2017
5.16
Jun 22. 2017
5.87
7 Trading Days
13.71%
Link
LONG
Jul 21. 2017
6.69
Jul 31. 2017
7.11
6 Trading Days
6.25%
Link
LONG
Sep 18. 2017
7.98
Oct 3. 2017
8.73
11 Trading Days
9.34%
Link
LONG
Dec 28. 2017
8.73
Jan 16. 2018
10.46
11 Trading Days
19.84%
Link
LONG
May 31. 2018
6.31
Jun 8. 2018
6.86
6 Trading Days
8.64%
Link
LONG
Jun 11. 2018
7.00
Jun 25. 2018
13.03
10 Trading Days
86.15%
Link
LONG
Jul 12. 2018
12.77
Jul 26. 2018
14.31
10 Trading Days
12.09%
Link
Company Information
Stock Symbol
GLMD
Exchange
NasdaqCM
Company URL
http://www.galmedpharma.com
Company Phone
97236938448
CEO
Allen Baharaff
Headquarters
-
Business Address
16 ZE'EV TYOMKIN ST. (4TH FL.), TEL AVIV, ISRAEL 6578317
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001595353
About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.